AMSBIO has progressed since 2000
Presenting new technology.

Established to pursue a healthier life for humans, AMSBIO has been conducting research since 2000. We are constantly striving to create a total solution for rapid diagnosis and testing tools that take into account the flora and fauna, natural and urban environments.

The vast network of countries, national institutions, universities, and hospitals can be created through IVD devices, RDT Rapid diagnostic test), IVD reagent, and NGS (Next-generation sequencing).

AMSBIO’s core is R & D. AMSBIO commits to improving the quality of the healthier life of humans through innovative diagnostic technologies by developing future IVD technology in continuous R&D.

AMSBIO has progressed since 2000
Presenting new technology.

Established to pursue a healthier life for humans, AMSBIO has been conducting research since 2000. We are constantly striving to create a total solution for rapid diagnosis and testing tools that take into account the flora and fauna, natural and urban environments.

The vast network of countries, national institutions, universities, and hospitals can be created through IVD devices, RDT Rapid diagnostic test), IVD reagent, and NGS (Next-generation sequencing).

AMSBIO의 핵심은 R&D 입니다. 지속적인 R&D 를 통해 미래 주요 IVD 기술을 개발하고
이를 인간의 삶에 반영할 수 있는 혁신적인 진단 및 기술을 만들어 우리 모두의 삶의 질을
향상시키는 것입니다.

Company History

AMSBIO History

AMSBIO has developed diagnostic devices and kits and various reagents for the bioindustry for the past 20 years.

  • HISTORY
  • 2021

    · Approved IVD medical device manufacturing

    · Ministry of Food and Drug Safety Approval IVD No. 21-506

    · Approved for domestic regular use

  • 2020

    · Approved IVD medical device manufacturing

    · Ministry of Food and Drug Safety Approval IVD No. 21-506

    · Approved for domestic regular use

  • 2018

    · Development of A+CheQ qPCR Avellino reagent

    · Development of A+CheQ LAMP device and reagent

    · Certification of A+CheQ qPCR device and reagent

    · Commencing NGS analysis service and NGS platform realization

    · Development of A+CheQ qPCR device

    · Completion of GMP facility (Yeoju site)

  • 2017

    · Development of SmartDOG (Extraction of nucleic acid and SP-PCR integrated device)

  • 2014

    · Development of DNA verification system based on microchip

    · Co-development of Dendrion chip for first detection of FMDV using SP-PCR (Immobilization of chip and improving hybrid efficiency)

    · First detection of AI using SP-PCR

  • 2011

    · Development of LABODx (molecular diagnostic device through electric signal)

    · Development of SP-PCR technology based on Lab-on-a-chip (DNA amplification on the surface of the chip)

    · First detection of Salmonella bacteria using SP-PCR

    · First detection of E.coil using SP-PCR

  • 2005

    · Production of pharmaceutical-related genetic analysis kit first in Asia

    · Development of superintelligent chip and application technology system

    · Launch TwinChip TM E.coil-6Koligo chip (AMS)

    · “Commence “GenePlorer”, launch TM Human-34 Koligo chip

    · Development of DNA chip system for disease prediction

    · Development of antibody for lung cancer treatment

    · Development of DNA chip based on genome diagnosis by disease groups

    · Register Gene analysis institute

    · Development of prototype chip for leukemia diagnosis

    · Development of new drugs for inflammation and cancer treatment through Transdisciplinary integration

    · Sole distributor for Korea : Agendia’s MammaPrint chip, Netherlands

  • 2000

    · Establishment of company

    · Venture business certification (by Korea government)

    · Development of Ultra-small automated protein chips as participating company of Strategic Alliance with Digital-Biotech [Medifron]

    · Commence production and service “Human 10K cDNA chip”

    · Commence production and service “Fly 6K cDNA chip”

    · Commence production and service “Mouse 6K cDNA chip”

    · Development of DNA chip for diagnosis of lung cancer and blood cancer

    · Development of chip for diagnosis of drug reaction for lung cancer prevention

    · Development of diagnostic biochip for the investigation of pathological phenomena of chronic myelogenous leukemia

    · Development of chip for targeted anti-cancer reactivity predictor gene